E3810 + E3810 + E3810
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Reflux Esophagitis
Conditions
Refractory Reflux Esophagitis
Trial Timeline
Oct 1, 2008 → Mar 1, 2010
NCT ID
NCT00770913About E3810 + E3810 + E3810
E3810 + E3810 + E3810 is a phase 2/3 stage product being developed by Eisai for Refractory Reflux Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00770913. Target conditions include Refractory Reflux Esophagitis.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Reflux Esophagitis were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00770913 | Phase 2/3 | Completed |
Competing Products
20 competing products in Refractory Reflux Esophagitis